Mouser Electronics Announces Partnership with DS PENSKE for Formula E Season 11 with Debut in Brazil
3.12.2024 17:09:00 CET | Business Wire | Press release
Mouser Electronics, Inc., the New Product Introduction (NPI) leader™ empowering innovation, is gearing up to sponsor the DS PENSKE Formula E racing team as they begin Season 11 at the Sambadrome in São Paulo, Brazil, on December 7. Mouser is sponsoring the team throughout the 2024/2025 ABB FIA Formula E World Championship racing season in collaboration with TTI, Inc. and valued manufacturers Molex and KYOCERA AVX.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203326874/en/

This is the first time that Brazil has hosted the Formula E season-opener, and the race will see two-time Formula E World Champion Jean-Éric Vergne joined by Maximilian Günther as they pilot the new GEN3 Evo car. (Photo: Business Wire)
This is the first time that Brazil has hosted the Formula E season-opener, and the race will see two-time Formula E World Champion Jean-Éric Vergne joined by Maximilian Günther as they pilot the new GEN3 Evo car. The GEN3 Evo is faster, stronger, and more agile than its predecessors and features an aggressive new body kit designed to be stronger, more robust and more aerodynamic. It also allows for all-wheel drive, a first for a Formula E car.
"Mouser is thrilled to continue our support of the DS PENSKE Formula E team," said Todd McAtee, Senior Vice President, Business Development for Mouser Electronics. "We're also excited to see what the new car can do. With acceleration 0-60mph, 30% faster than a current F1 car, this is sure to be an exhilarating season."
"TTI is pleased to team up again with Mouser to support DS PENSKE and promote this dynamic sport and its commitment to innovation and environmental responsibility," said Mike Morton, TTI Chief Executive Officer. "We will be looking forward to a winning year ahead."
"The new car promises to continue the evolution of Formula E and serves as a powerful showcase for the electric future of motorsports," said Fred Bell, Molex Vice President of Global Distribution. "Mouser and Molex have been proud supporters since the inception of Formula E, and we wish the DS PENSKE team a safe and successful season."
"We're delighted to collaborate with Mouser and TTI in our partnership with the DS PENSKE Formula E racing team for another exciting season," said Alex Schenkel, KYOCERA AVX Senior Vice President of Global Sales.
Formula E will complete a 16-race season spanning ten iconic venues as it continues to pioneer all-electric racing. The globe-trotting schedule includes a return to Miami, Florida, double-headers in Tokyo and Monaco, and Formula E's first-ever trip to Jeddah in Saudi Arabia. A double-header finale in London, England, rounds out the largest Formula E race calendar to date.
Formula E cars are powered solely by electricity and represent a vision for the future of the motorsports industry, serving as a framework for research and development around zero-emission motoring. Racing is all about speed and endurance, and racing partnerships are an innovative way for Mouser to communicate its performance-driven business model and promote the newest technologies from its manufacturer partners.
To learn more about the Mouser-backed DS PENSKE Formula E racing team and view the Formula E schedule, visit https://www.mouser.com/formula-e/.
For more Mouser news and our latest new product introductions, visit https://www.mouser.com/newsroom/.
As a global authorized distributor, Mouser offers the widest selection of the newest semiconductors, electronic components and industrial automation products. Mouser's customers can expect 100% certified, genuine products that are fully traceable from each of its manufacturer partners. To help speed customers' designs, Mouser's website hosts an extensive library of technical resources, including a Technical Resource Center, along with product data sheets, supplier-specific reference designs, application notes, technical design information, engineering tools and other helpful information.
Engineers can stay abreast of today's exciting product, technology and application news through Mouser's complimentary e-newsletter. Mouser's email news and reference subscriptions are customizable to the unique and changing project needs of customers and subscribers. No other distributor gives engineers this much customization and control over the information they receive. Learn about emerging technologies, product trends and more by signing up today at https://sub.info.mouser.com/subscriber/.
About Mouser Electronics
Mouser Electronics is an authorized semiconductor and electronic component distributor focused on New Product Introductions from its leading manufacturer partners. Serving the global electronic design engineer and buyer community, the global distributor's website, mouser.com, is available in multiple languages and currencies and features more than 6.8 million products from over 1,200 manufacturer brands. Mouser offers 28 support locations worldwide to provide best-in-class customer service in local language, currency and time zone. The distributor ships to over 650,000 customers in 223 countries/territories from its 1 million-square-foot, state-of-the-art distribution facilities in the Dallas, Texas, metro area. For more information, visit https://www.mouser.com/.
Trademarks
Mouser and Mouser Electronics are registered trademarks of Mouser Electronics, Inc. All other products, logos, and company names mentioned herein may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203326874/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom